Cervical Cancer

>

Latest News

Tisotumab Vedotin Earns Japanese Approval in Advanced Cervical Cancer
Tisotumab Vedotin Earns Japanese Approval in Advanced Cervical Cancer

March 28th 2025

Tisotumab vedotin elicited a median OS of 11.5 months vs 9.5 months with chemotherapy in advanced cervical cancer in the phase 3 innovaTV 301 trial.

Increased incidence and mortality rates for cervical cancer among rural women in the US may result from barriers to access to care.
Women in Rural Regions Experience Greater Cervical Cancer Incidence/Mortality

March 25th 2025

Patients who had recurrence in the radiation field experienced similar responses vs those with recurrence outside the radiation field.
Immunotherapy Sustains Responses in Radiated Endometrial/Cervical Cancer

March 18th 2025

Despite all groups completing chemoradiation within 56 days, delays contributed to a nonsignificant difference in length between Black vs White patients.
Increased Wait Times Observed for Black/Hispanic Patients With Cervical Cancer

March 18th 2025

Cancer Vaccine/Durvalumab Yields Efficacy in HPV+ Cervical Cancer
Cancer Vaccine/Durvalumab Yields Efficacy in HPV+ Cervical Cancer

March 16th 2025

Video Interviews
Podcasts
The FDA approval of pembrolizumab plus chemoradiation benefits patients with stage III to IVA cervical cancer based on findings from the KEYNOTE-A18 trial, according to Jyoti S. Mayadev, MD.
Julianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.
Oncology Peer Review On-The-Go

More News